RankAlpha logo
Back to Rankings

CRVS

CorvusB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Soquelitinib has multiple shots on goal across PTCL, atopic dermatitis, asthma, hidradenitis suppurativa, and China development. Enrollment is reported on track, early atopic dermatitis data remain supportive, and cash runway extends into Q2 2028.
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29.
What can break
Late-2026 China, asthma, and hidradenitis suppurativa milestones may be delayed or produce inconclusive data.
Momentum
10
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $23.00 · Bear $7.50Analysis 2026-08-08; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $33.14
Why
Momentum10 · Δ7d +1.8
Value41 · Δ7d -0.1
Sentiment81 · Δ7d -13.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29.
  • • Sentiment remains the lead driver in the composite, 7D delta -13.2.

Contradictions & invalidation

  • • Late-2026 China, asthma, and hidradenitis suppurativa milestones may be delayed or produce inconclusive data.
  • • No reliable analyst revision, consensus surprise, or post-print market-reaction attribution was available.
  • • The thesis remains clinical and binary, with no validated consensus surprise, analyst revision, or target-change signal in the packet.

Catalyst clock

2026-10-29

Q2 update preserved clinical execution and runway

Lead driver: Sentiment · See AI snapshot
Momentum
10
8% active weight
Current posture
7d trendFlat
Δ7d
+1.8
Δ21d
+3.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
81
45% active weight
Current posture
7d trendSoftening
Δ7d
-13.2
Δ21d
-7.8
Why this grade

Composite grade B. Momentum 9.6 / Value 40.6 / Sentiment 81.4

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method

B+
Bull case
20%
Probability
Target price
$23.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$885.79M
Beta
0.70
Shares Out
84.12M
P/E (TTM) · Derived
-54.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-20.41
Rev YoY
-
EPS YoY
+89.1%
Gross Margin
-
Op Margin
-
Net Debt
-$55.81M
Current Ratio
16.16
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data